Target intelligence / Profile preview

Gut epithelial barrier and blood–brain barrier (GEB/BBB)

Target
GEB/BBB
Molecular classification
Tight junction protein, Efflux transporter, Cell adhesion molecule, Solute carrier transporter
01

Overview

The gut epithelial barrier and the blood-brain barrier (BBB) are complex physiological systems that serve as the primary gatekeepers for the body's internal environment and the central nervous system, respectively. The gut barrier consists of a single layer of epithelial cells joined by tight junctions that regulate the absorption of nutrients while preventing the entry of luminal pathogens and toxins (PubMed: 23426535). The BBB is a highly specialized endothelial interface that maintains the unique microenvironment of the brain by restricting the passage of solutes and potentially harmful substances from the blood (PubMed: 16625214). These barriers are functionally linked through the gut-brain axis, where increased intestinal permeability (often termed 'leaky gut') can trigger systemic immune responses that subsequently compromise BBB integrity, contributing to neurodegenerative and autoimmune disorders (PubMed: 25880519). While not a single molecular target, specific components of these barriers, such as tight junction proteins (claudins, occludins) and efflux transporters (P-glycoprotein), are major focuses for drug delivery strategies and therapeutic intervention in inflammatory and neurological diseases.

Other names
Intestinal mucosal barrierBlood-cerebral barrierGut-brain axis barriersIntestinal epithelial barrier
02

Mechanism of action

Modulation of tight junction assembly, inhibition of ATP-binding cassette (ABC) efflux transporters, and osmotic disruption of endothelial cell-cell junctions.

03

Biological functions

Selective permeabilityHomeostasisImmune exclusionNeuroprotectionNutrient absorptionXenobiotic efflux
04

Disease associations

Inflammatory bowel diseaseCeliac diseaseMultiple sclerosisAlzheimer's diseaseParkinson's diseaseNeuroinflammationSepsis
05

Safety considerations

Neurotoxicity due to unintended drug entry into the CNSSystemic inflammation from pathogen translocationLoss of metabolic homeostasisIncreased risk of seizures or encephalopathy
06

Interacting drugs

Larazotide acetate

4 more in the full profile.

07

Biomarkers

ZonulinS100 calcium-binding protein B (S100B)Intestinal fatty acid-binding protein (I-FABP)Claudin-5Glial fibrillary acidic protein (GFAP)

Beyond the preview

Go deeper on Gut epithelial barrier and blood–brain barrier (GEB/BBB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut epithelial barrier and blood–brain barrier (GEB/BBB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call